IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
OHSU Knight Cancer Institutemonoclonal_antibodyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Fred Hutchinson Cancer Center | Phase 2 | BB |
Cyclophosphamide OHSU Knight Cancer Institute | Phase 2 | B |
Rapamycin OHSU Knight Cancer Institute | Phase 2 | B |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2 | B |
Monomethyl Fumarate Fred Hutchinson Cancer Center | Phase 2 | B |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →